News

Sanofi’s Hyderabad GCC Expansion to 4,500+ Specialists Signals India’s Rising Role in Global Pharma Innovation

French drugmaker Sanofi has nearly doubled the workforce capacity at its Hyderabad Global Capability Centre, reinforcing India’s position as a strategic hub for AI, R&D and pharma services.

• By PharmaNews Live Desk
• Hyderabad
• Feb 17, 2026

News

French pharmaceutical giant Sanofi Healthcare India Pvt. Ltd. has announced a major expansion of its Global Capability Centre (GCC) in Hyderabad, boosting the centre’s workforce capacity from around 2,600 to approximately 4,500 specialists. The move underlines India’s growing importance as a global destination for high-value pharma services, research and digital innovation.

Major Boost to Hyderabad Hub

The expansion, which adds more than 2.7 lakh square metres of workspace at the existing Hitech City campus, positions the Hyderabad facility among the top three pharma GCCs in India by scale and scope, according to company officials.

Inaugurated on Monday alongside senior Sanofi leaders by Duddilla Sridhar Babu, Telangana’s Minister for IT, industries and commerce, the enhanced centre is designed to support global operations across a broad spectrum of functions.

From Support Services to Strategic Innovation

Originally established in 2019 with a focus on medical services, the Hyderabad GCC has evolved into a strategic hub handling advanced functions including:

• Research and development (R&D)
• Artificial intelligence (AI) and digital innovation
• Data analytics
• Medical affairs
• Commercial operations
• Finance, procurement and people services

According to Sanofi executives, the centre underscores the company’s shift towards an R&D-driven, AI-powered biopharma model — with India’s deep talent pool in innovation and data science playing a critical enabling role.

Leadership Perspectives

Madeleine Roach, Executive Vice-President and Head of Business Operations at Sanofi, highlighted the strategic purpose behind the expansion, noting that India’s exceptional talent base is key to accelerating the company’s transformation and advancing its mission of improving lives globally.

Telangana Chief Minister Revanth Reddy said the move reflects the state’s rising stature as a global hub for innovation-led life sciences, contributing to high-skilled employment and scientific capability building.

Minister Sridhar Babu added that the expanded GCC illustrates Hyderabad’s evolution from a largely manufacturing-oriented base to a centre of strategic innovation and digital operations for global biopharma.

Strategic and Economic Context

Sanofi’s decision comes as part of broader corporate investments in India’s life sciences ecosystem. Reuters reporting notes that the company is backing the expansion with a multi-hundred-million-dollar investment, aligning with a trend of multinational firms developing innovation-driven GCCs in India.

Industry data show India hosts over 1,700 GCCs employing nearly 2 million professionals, with projections to exceed 2,400 centres by 2030 as companies increasingly tap into the country’s talent and competitive advantages.

With the expanded Hyderabad GCC now supporting advanced capabilities in areas like AI, data analytics and enterprise operations, Sanofi’s investment reinforces the city’s role as a strategic node in the global pharmaceutical services landscape.